Lohan C, Diamantopoulos A, LeReun C, et al. Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation. BMJ Open Gastro 2019;6:e000302. doi: 10.1136/bmjgast-2019-000302

This article was previously published with incorrect information regarding dosing values in the main body, Tables 2 and 9, footnote of Figure 1 and supplementary material.

The correct dosage, considered in the analysis, was 5 mg/kg given as an intravenous infusion induction regimen at 0, 2, and 6 weeks followed by a maintenance regimen of 5 mg/kg IV every 8 weeks thereafter.